Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• Breast cancer (BC) is a leading cause of cancer death globally, with metastasis to distant organs being the primary cause.
• Brain metastases (BM) develop in approximately 30% of metastatic BC patients, representing a significant clinical challenge with limited treatment options.
• Understanding the molecular drivers of BCBM is crucial for improving patient outcomes.

Purpose of the Study:

• To review the influence of BC molecular subtypes and gene expression on the development and prognosis of breast cancer brain metastasis (BCBM).
• To connect current research findings on BCBM mechanisms with existing and emerging therapeutic strategies.
• To identify critical knowledge gaps and future research directions in BCBM.

Main Methods:

• Literature review of scientific articles focusing on breast cancer, brain metastasis, molecular subtypes, gene expression, and therapeutic strategies.
• Analysis of genetic and molecular mechanisms contributing to BCBM, including circulating tumor cells (CTCs), epithelial-mesenchymal transition (EMT), and cancer stem-like cells (CSCs).
• Synthesis of research findings with clinical implications and therapeutic approaches.

Main Results:

• HER2-positive and triple-negative BC subtypes are associated with a higher risk of developing BCBM.
• Specific molecular mechanisms, including increased CTCs, EMT, and CSCs, facilitate BCBM formation and progression.
• These BC characteristics influence patient prognosis and are targets for therapeutic interventions.

Conclusions:

• BC molecular subtype significantly impacts BCBM development and patient prognosis.
• Targeting mechanisms like CTCs, EMT, and CSCs holds promise for preventing and treating BCBM.
• Further research is needed to fully elucidate BCBM pathogenesis and develop more effective therapies.